- Home
- OGN
OGN
Organon & Co.
as 04-25-2025 4:00pm EST
Upcoming Earnings Alert:
Get ready for potential market movements as Organon & Co. OGN prepares to release earnings report on 01 May 2025.
| Founded: | 1923 | Country: | United States |
| Employees: | N/A | City: | JERSEY CITY |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $20.60 | AVG Volume (30 days): | 4.3M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 3.33 | EPS Growth: | -16.54 |
| 52 Week Low/High: | $10.45 - $23.10 | Next Earning Date: | 05-01-2025 |
| Revenue: | $6,403,000,000 | Revenue Growth: | 2.23% |
| Revenue Growth (this year): | -1.81% | Revenue Growth (next year): | 0.91% |
Latest Organon & Co. News
OGN Breaking Stock News: Dive into OGN Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
OGN: What does Argus have to say about OGN?
Argus Research
10 days ago
OGN: Lowering target price to $12.00
Business Wire
10 days ago
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
Business Wire
11 days ago
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
Argus Research
17 days ago
OGN: Lowering target price to $13.00
Zacks
24 days ago
Why Organon (OGN) Could Beat Earnings Estimates Again
Argus Research
24 days ago
OGN: What does Argus have to say about OGN?
Business Wire
25 days ago
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
Compare OGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OGN Organon & Co. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.